Caplin Point — a cash machine off the beaten path
Caplin Point Laboratories Ltd
Snapshot
Caplin Point makes simple, essential medicines — tablets, injections, ointments, eye drops — and sells most of them in places the big drug companies never bothered with: Latin America, and increasingly Africa. More than 65% of what it sells is on the World Health Organisation’s “essential drugs” list. It owns its distribution all the way down to the pharmacy counter, which is the whole trick. Lately it has bolted on a second engine — selling sterile injectables into the tightly-regulated United States. Market cap ₹19,030 cr, share price ₹2,504 (near its ₹2,560 high; low ₹1,500), P/E 29.7, price-to-book 5.3×, return on equity ~21%, return on capital ~25%, and essentially no debt. As of 2026-06-20, from the screener snapshot.
What kind of animal it is: a Great little franchise in its chosen corner — fat margins, gushing cash, built by a frugal owner — that is now spending to grow a heavier, lower-margin US manufacturing arm. The catch is the price: the quality is no secret.
The verdict in one box
| Lens | Result |
|---|---|
| QGLP score (Motilal Oswal) | 21 / 25 — Quality 9.5/12 · Growth 6/6 · Longevity 5/5 · Price 0.5/2 |
| Buffett rubric | 7.5 / 10 PASS |
| Business bucket | Great, drifting toward Good as US manufacturing adds capital |
| Wealth-creator type | Enduring · Consistent (profit rose every year for 11 years) |
| Economic Profit | +₹267 cr (RoE ~20.6% − CoE 12% on ~₹3,110 cr net worth) — clearly creating value |
| Margin-of-safety price band | ₹1,750–₹2,150 (where PEG nears 1×). CMP ₹2,504 is fair-to-demanding — priced for the quality |
One plain-English sentence: A Great business and a genuine wealth creator, run by an honest, frugal owner — currently priced for what it is, with no obvious discount but cheaper than every quality peer.
In plain English
Picture a man who, in the 1990s, had a small drug company going nowhere and his back against the wall. Instead of fighting the giants in America and Europe, C.C. Paarthipan walked the other way — into Latin America and West Africa, markets so hard to operate in (politics, geography, paperwork) that nobody big wanted them. He sold cheap, good-quality essential medicines to the poorest people, and slowly he stopped being just a supplier and started owning the whole chain: the registrations, the distribution, the 22,000 pharmacy touchpoints. That is Caplin Point. It is the toll-booth, not just the truck.
Why does that make money? Because once you own the road into a difficult market, competitors can’t just show up — they’d have to rebuild the road. Caplin’s operating margin has climbed from 24% to 35% over a decade while revenue grew eight-fold and profit thirteen-fold. Rising margins on rising sales is the financial fingerprint of pricing power. It funded all of it from its own pocket — the company carries no debt and never sold new shares to outsiders. Profit has gone up every single year for eleven years straight, never once falling. You don’t see that often.
So what’s happening now? Caplin is using its mountain of cash to build a second business: making sterile injectable drugs (the hard, high-barrier kind) and selling them into the United States through its own front-end. This is the growth story everyone is watching. It’s promising — the US arm grew ~29% last year and the front office turned its first profit — but it’s also a different, heavier, lower-margin game than the LatAm cash machine, and most of the promised scale is still guidance, not yet results.
Two things keep this from being a slam-dunk. First, the old magic — getting paid before it paid its own suppliers (negative working capital) — has faded. The company now waits longer to collect its money (receivables up to 138 days) and holds more stock, so cash trickles in a bit slower than the profit it reports. Second, and simply: the market knows all of this. At ~30× earnings the stock is the cheapest of its quality peers but is sitting near its all-time high. You’re buying a wonderful business at a fair-to-full price, not a bargain.
Sitting down with the management
If Buffett and Raamdeo Agrawal sat across from C.C. Paarthipan for an afternoon, I think they’d like him a great deal — and then ask one pointed question about his cash.
Start with the man. Paarthipan is a first-generation entrepreneur who began as a medical representative in the 1980s — a salesman, knocking on doctors’ doors. He built Caplin, nearly lost it in a botched 1990s expansion, and then did the rarest thing in business: he changed his mind and rebuilt the model from scratch, choosing the markets no one else wanted. That is not an empire-builder’s story; it’s an operator’s. His stated creed — “the road less traveled,” serve the bottom of the pyramid — actually matches what the company does. Buffett looks for brains, passion and integrity, integrity first. The passion here is obvious.
Now the integrity, where the receipts matter most. Three facts tell you who you’re dealing with. One: the founder takes no salary, and total top-management pay is barely 1% of profit — about ₹0.57 cr against ₹540-plus crore of earnings (HARD — FY25 directors’ report). Two: he owns 70.6% of the company and has not pledged a single share (HARD — Mar-2026 shareholding). Three: in eleven years the share count has not moved — equity capital sits at the same ₹15 cr it was a decade ago. No dilution, no fancy ESOP raids on the owners, no debt. This is a man eating his own cooking and not helping himself to seconds at your expense. There are no auditor qualifications, no related-party games I can find, no governance theatre. The forensic red-flags mostly stay quiet.
The capital-allocation scorecard is where it gets interesting. The one-dollar test — did each rupee he kept create at least a rupee of market value? — passes overwhelmingly: he turned a tiny company into a ₹19,000 cr one without selling stock or borrowing. But here’s the pointed question. Caplin now sits on a cash hoard worth roughly twice its annual profit, much of it parked in treasury earning maybe 7% while the core business earns 20-25%. That idle cash quietly drags the blended return down (it’s the main reason return-on-capital has slid from 68% to 25% — not because the business got worse, but because the denominator filled up with lazy money). And the dividend is a stingy ~5% of profit. So the verdict on candor and frugality is a clear tick; the verdict on deploying the cash is “finally getting on with it” — the ₹1,000 cr+ US/API capex plan is the cash starting to work. The one knock on communication: this is a low-float, owner-driven company that doesn’t court the market, and its concall transcripts are genuinely hard to even get hold of. You’re trusting the man more than the disclosure.
Succession is identified but not yet tested: son Vivek Partheeban is Vice-Chairman, and Dr. Sridhar Ganesan is a professional MD with 40 years in global pharma. The bench exists; the founder is still the engine.
Would they shake hands on this management? Yes — readily. The one thing that would change their mind: if that growing pile of receivables ever stopped turning into actual cash, or if the cash hoard were one day spent on an ego-acquisition outside the circle. Neither has happened. Watch both.
What’s on the horizon (live-issues tracker)
Three live threads will decide the next one-to-three years. In plain terms:
1. The US injectables ramp — the whole growth story. 🟡 Mixed / early. Caplin is building a US business in sterile injectables (the hard-to-make, high-barrier drugs) through its arm Caplin Steriles, plus a new oncology/complex-injectables plant and its own US sales front-end. Why it matters: this is the engine that’s supposed to keep growth above 15% as the LatAm base gets larger. How’s it going? The numbers are early-stage encouraging but not yet the inflection: US revenue reached ₹471 cr, up ~29% in FY26 (HARD — Q4 FY26 presentation, 14 May 2026), and the US front-end turned profitable in its first full year on ~$11M of sales (SOFT — Q4 FY26 call). Management has held its guidance of ~$100M of Caplin Steriles revenue by FY27 (SOFT — broker notes, May 2026). That $100M is the single most testable promise in this story. They also bought 10 approved US drug filings (ANDAs) addressing a ~$473M market (HARD — 2025) — buying a runway rather than waiting years to build one. The bear read: US generic injectables is a brutal, price-eroding market, US segment margins (~11% on revenue) are a fraction of the LatAm core’s (~34%), and “scaling up” has been the promise for a while.
2. Cutting the China cord — backward integration. 🟡 Early. Caplin sources roughly 27–35% of its inputs from China (SOFT — H1 FY26 call). It’s building a greenfield API plant strictly to feed itself — explicitly not to sell raw drug ingredients to others (HARD — Q3 FY26 call, 5 Feb 2026). Sensible de-risking; too soon to see it in the numbers.
3. Working capital — the quiet worry. 🔴 Drifting the wrong way. The famous negative-working-capital model has reversed. Receivable days rose to 138 (from 117 two years ago), inventory to 181 days, and the cash-conversion cycle to 194 days (HARD — Screener, Mar-2026). Management says ~two-thirds of inventory is sitting at customer sites or in transit, and aims to keep receivables under 120 days (SOFT — Nov-2025 call). This is the thing most likely to disappoint: profit converting to cash more slowly, year after year, is exactly the pattern a careful investor watches for.
The watch-list (check next quarter):
- Caplin Steriles revenue run-rate vs the $100M-by-FY27 target.
- US segment margin — is it climbing toward the group’s, or stuck near 11%?
- Receivable days — does it fall back under 120, or push past 140?
- Operating cash flow ÷ net profit — has it climbed back above ~90% (it was ~80–88% lately)?
- The ₹1,000 cr+ capex — spent on schedule, or slipping?
- Promoter holding & pledge — must stay ~70.6% and unpledged.
QGLP scorecard (the Motilal Oswal lens) — the receipts
Score each 0 / 0.5 / 1. “RoE” = profit per ₹100 of owners’ money; “RoCE” = profit per ₹100 of all capital used; “OPM” = operating profit margin; “working capital” = cash tied up running the business.
| # | Question | Score | Evidence |
|---|---|---|---|
| Quality of Business | 4.5/6 | ||
| 1 | Large opportunity? | 1 | Global essential-generics + US injectables + Africa runway; TAM huge vs ₹2,187 cr sales |
| 2 | Industry structured favourably? | 1 | Chose low-competition difficult markets; OPM rose 24%→35% over a decade = pricing discipline |
| 3 | Defensible moat? | 1 | First-mover owned distribution (22,000 LatAm touchpoints), 4,000+ licences; RoCE >25% for 10 yrs |
| 4 | RoE & RoCE >15% consistently? | 1 | RoE ~20.6%, RoCE 24.6% latest; both >15% every year for 10 yrs |
| 5 | Asset-light / low capital intensity? | 0.5 | 60:40 in-house/outsourced & FCF-positive, BUT ₹1,000 cr+ capex + CWIP ₹209 cr now adding weight |
| 6 | Terms of trade (negative working capital)? | 0 | Cash-conversion +194 days (was −67 a decade ago); Debtors/Creditors ~169% — it now banks customers |
| Quality of Management | 5/6 | ||
| 7 | Unquestionable integrity? | 1 | No pledge, no dilution in 10 yrs, founder no salary, clean audits; mild cash-conversion watch only |
| 8 | Proven execution? | 1 | 8× revenue, 13× profit in 10 yrs — delivered |
| 9 | Growth mindset & vision? | 1 | US regulated push, backward integration, biosimilars optionality |
| 10 | Superior capital allocation? | 1 | Reinvested at ~20% RoE, debt-free, no value-destroying M&A; only ding = idle cash hoard |
| 11 | Clear succession? | 0.5 | Son (Vice-Chairman) + professional MD identified; founder still central |
| 12 | Minority interests protected? | 0.5 | No leakage, frugal pay — but payout only ~5%, cash hoarded not returned |
| Growth | 6/6 | ||
| 13 | Structural tailwind? | 1 | EM pharma + US generics grow faster than GDP |
| 14 | Volume-led (not just price)? | 1 | Driven by registrations/products/geographies, not price hikes |
| 15 | Operating leverage? | 1 | OPM 24%→35% as sales 8בd |
| 16 | Manageable leverage? | 1 | Essentially debt-free (₹5 cr borrowings) |
| 17 | Market-share gain potential? | 1 | Gaining share in LatAm; US barely started; Africa 5% |
| 18 | Earnings growth >15% CAGR? | 1 | PAT CAGR ~21% (5yr) / ~24% (10yr) |
| Longevity | 5/5 | ||
| 19 | Relevant for 10–15 yrs? | 1 | Essential generic drugs — durable, low-disruption demand |
| 20 | Extend competitive-advantage period? | 1 | Core RoCE stays ~2× cost of capital; moat widening into regulated markets |
| 21 | Sustain growth-advantage period? | 1 | Long runway: US, Africa, biosimilars, API all early |
| 22 | Diversification headroom? | 1 | Geographic + product optionality is large |
| 23 | Adaptive, resilient culture? | 1 | Survived 1990s near-death; reinvented the model more than once |
| Price | 0.5/2 | ||
| 24 | Valuation reasonable (PEG)? | 0.5 | PEG = 29.7 ÷ 21.9 = 1.36 (between 1–2) |
| 25 | Margin of safety (PEG<1 or payback<1)? | 0 | PEG 1.36, 5-yr payback ~3.3× — neither hurdle cleared |
| Total | 21/25 | Quality 9.5 · Growth 6 · Longevity 5 · Price 0.5 |
The pattern: Quality and Growth and Longevity are very nearly perfect — this is a textbook wealth creator on the checklist. The two soft spots both sit at the edges of “quality”: the working-capital model has eroded (Q6), and the cash isn’t being fully put to work or returned (Q12). Everything standing between this and a clear buy-zone is Price.
Buffett lens (the Berkshire-letters read)
| # | Test | Result | Evidence |
|---|---|---|---|
| 1 | Good boat? (business > management) | PASS | RoCE ~25%, FCF-positive, debt-free — a Great boat (drifting toward Good as US capex lands). “A good managerial record is far more a function of what boat you get into.” |
| 2 | Moat + franchise + pricing power | PASS | OPM 24%→35% through a decade; RoE > cost of capital 10 of 10 years |
| 3 | See’s test (high returns, little capital) | PARTIAL | Historically negative-WC and asset-light; now feeding ₹1,000 cr capex + rising working capital |
| 4 | Capital allocation — one-dollar test | PASS | No dilution in 10 yrs; ~₹500 cr → ~₹19,000 cr of market value from retained earnings. Ding: idle cash |
| 5 | Owner-oriented, candid management | PASS | 70.6% skin in the game, no salary, no pledge; caveat — thin disclosure, low float |
| 6 | Integrity / forensic (cash backs profit?) | PARTIAL | OCF ÷ PAT ~80% lately; receivables rising faster than sales — the one yellow flag |
| 7 | Circle of competence / predictability | PASS | Simple essential drugs; looks much like it did 10 yrs ago |
| 8 | Mr. Market — gift or trap now? | PARTIAL | P/E ~30, near all-time high, PEG 1.36 — fair for the quality, but no fearful discount |
| 9 | Patience / compounding runway | PASS | Long runway (US/Africa/biosimilars early) at ~20% RoE |
| 10 | The honest red flag | (see below) | Working capital + cash conversion + US-ramp-is-guidance |
Tally: 6 PASS + 3 PARTIAL = 7.5 / 10 — a real business with real, nameable gaps, just shy of Buffett-grade. The gaps are the same ones QGLP found.
The See’s test, spelled out. See’s Candies was Buffett’s archetype: tiny reinvestment, a fountain of cash. Caplin used to be pure See’s — it got paid up front in LatAm and barely tied up capital. That has changed. It’s now reinvesting hard (₹1,000 cr+) and tying up more working capital, so it’s migrating from a See’s-style cash fountain toward a “Good company that must feed capital to grow.” Still throws off free cash (~₹275 cr in FY26), but the conversion is slipping — hence PARTIAL.
The one-dollar test, spelled out. Has each retained rupee created a rupee of market value? Emphatically yes: management kept almost all the profit (5% payout), never sold stock, never borrowed — and turned a sub-₹500 cr company into a ₹19,000 cr one. By Buffett’s own arithmetic, retention here has been spectacularly justified. The only asterisk is the slug of cash now earning treasury yields instead of 20% — value preserved, not multiplied. The capex plan is that cash finally going to work.
The honest red flag (test 10). The single strongest reason to doubt this is a continuing wealth creator: the cash-conversion story. Profit is up every year, but the business now collects later (138-day receivables) and stocks more (181-day inventory), so reported earnings turn into bankable cash more slowly than they used to. If that trend keeps drifting, “growth” can quietly become receivables on a balance sheet rather than money in the till — the classic “credit the P&L, debit the balance sheet” trap Agrawal warns about. The numbers don’t yet confirm the trap (cash does keep coming, FCF is positive, governance is clean), but they no longer fully refute it either. This is the thing to watch, above all else.
The framework metrics
- Economic Profit = avg net worth × (RoE − 12%) = ~₹3,110 cr × (20.6% − 12%) ≈ +₹267 cr. Positive — Caplin earns well above the cost of its owners’ money. (Creating value.)
- Terms of Trade = Debtors ÷ Creditors ≈ ₹827 cr ÷ ₹490 cr ≈ 169% — unfavourable, and the wrong direction vs the negative-WC golden era.
- 5-yr Payback = market cap ÷ projected cumulative 5-yr profit = ₹19,030 cr ÷ ~₹5,800 cr ≈ 3.3× (assumes ~20% PAT CAGR). Far above the <1× multi-bagger signal — you’re paying up for quality.
- PEG = P/E ÷ growth = 29.7 ÷ 21.9 = 1.36 — modestly above the 1.0 discipline line.
- RoE − CoE spread = ~8.6 percentage points; RoE has cleared 15% in all of the last 10 years.
- Consistent vs Volatile = Consistent — net profit rose every year for 11 years (41 → 650), never fell. Value it on P/E, not P/B.
Peer comparison
The closest quality peers are mid-cap Indian pharma names that, like Caplin, lean on emerging markets and/or injectables and earn high returns.
| Company | Mkt cap | CMP | P/E | P/B | RoE | RoCE | OPM | Latest sales |
|---|---|---|---|---|---|---|---|---|
| Caplin Point | ₹19,030 cr | ₹2,504 | 29.7 | 5.3× | 20.6% | 24.6% | 35% | ₹2,187 cr |
| Ajanta Pharma | ₹38,295 cr | ₹3,065 | 36.3 | 8.5× | 25.4% | 32.3% | 26% | ₹5,453 cr |
| J B Chemicals | ₹35,219 cr | ₹2,194 | 49.0 | 8.5× | 18.9% | 25.4% | 27% | ₹4,148 cr |
| Gland Pharma | ₹36,275 cr | ₹2,199 | 34.7 | 3.5× | 10.7% | 15.1% | 25% | ₹6,431 cr |
What it says: On absolute QGLP arithmetic (PEG 1.36, payback 3.3×) Caplin fails the strict price bar — but relative to its asset class it is the cheapest quality name on the board. It trades at ~30× earnings versus 36–49× for the branded-EM peers (Ajanta, J B), while carrying the highest operating margin (35%) in the group and elite returns. Gland is optically cheaper on price-to-book, but its returns (RoE ~11%) are less than half Caplin’s — it’s a different, lower-quality animal (a pure US injectables contract-maker getting squeezed). Caplin’s distinctive edge is the LatAm owned-distribution moat that none of these peers have; the peer set’s edge over Caplin is scale and, in Ajanta’s case, a higher return on capital. The absolute lens (a patient value-investor) says “wait for a dip”; the relative lens (a sector-allocator) says “this is the value pick of the quality bunch.” Both are true; they answer different questions.
Latest quarter & what’s happening now
Q4 FY26 (reported 14 May 2026, HARD): revenue ₹600 cr (+19%), net profit ₹170 cr (+19%), OPM ~34%. Full-year FY26: revenue ₹2,187 cr (+13%), PAT ₹650 cr (+20%), RoE ~23%, debt-free, net worth +26% YoY; a ₹4.00 interim dividend declared.
Concall colour (SOFT — sourced via secondary coverage; Caplin’s own transcript PDFs returned a certificate error and could not be fetched directly): management reiterated the ~$100M Caplin Steriles (US) revenue target by FY27, flagged ₹1,000 cr+ capex over 18–24 months for oncology/complex injectables and API backward-integration, and pointed to non-US regulated-market filings (Canada, EU, Australia, Mexico, Brazil) as the next leg. Note: because the primary transcripts couldn’t be pulled, treat the forward guidance figures as indicative until checked against the filed transcript.
Where the two lenses agree — and disagree
They agree on almost everything: both call this a genuinely high-quality, moat-protected, well-run, honestly-financed wealth creator (QGLP 21/25; Buffett 6 clean PASS). Both also flag the identical two soft spots — the eroded working-capital model and the not-cheap price.
They diverge in one subtle place worth naming. QGLP’s checklist, being a quality audit, happily gives Caplin near-full marks on integrity and capital allocation. The Buffett lens, which weights the cash-versus-accounting question harder, downgrades the same facts to PARTIAL on test 6 (does cash back the profit?). That’s the signal: a scorecard sees clean governance and ticks the box; Buffett’s forensic instinct says “the profit is real, but watch how slowly it’s turning into cash.” The divergence isn’t a contradiction — it’s a magnifying glass on the one number that matters most from here: cash conversion.
Margin-of-safety price band
Not a recommendation — just the framework’s arithmetic.
- PEG ≤ 1 discipline: at ~21% growth, that implies a P/E around 21× — roughly ₹1,750–₹1,800 on FY26 earnings (₹84 EPS), or ~₹2,100 on a forward FY27 estimate. Call the disciplined accumulation zone ₹1,750–₹2,150.
- 5-yr payback ≤ 1× is essentially unreachable for any compounder this good (it would need a price near ₹760) — note it, then set it aside; it’s the wrong yardstick for a quality name.
- Mr. Market read on CMP ₹2,504: the stock sits near its all-time high with PEG at 1.36. That’s not greed, but it’s certainly not fear — there’s no margin of safety in the price today. This is a wonderful business at a fair-to-full price.
So: the quality becomes cheap below ~₹2,150 and outright attractive on the QGLP price test toward ₹1,750. At ₹2,504 you’re paying for what you’re getting — defensible if you value the franchise and the runway, but you are not being handed a discount. The relative-value caveat stands: even here, it’s the least-expensive quality name in its peer group.
Conviction texture
The bull case, at its strongest: You’re buying a debt-free, founder-owned cash machine with a real, hard-to-copy moat (LatAm owned distribution), a 35% operating margin, an 11-year unbroken record of rising profit, and a frugal, honest promoter with 70% skin in the game and no salary. On top of that sits a genuine second growth engine — US injectables — that is still early and barely in the numbers. Profit has compounded ~20%+ for a decade and the runway (US, Africa, biosimilars, API) is long. It’s the cheapest quality name in its peer set. Compounders like this rarely look cheap; you pay up and let time do the work.
The bear case, at its strongest: The negative-working-capital magic that made Caplin special is gone — receivables and inventory keep rising, cash conversion has slipped to ~80%, and that’s the exact early signature of growth that lives on the balance sheet rather than in the bank. The US ramp is still mostly a promise (the $100M target keeps being “next year”), and US generic injectables is a margin-eroding knife-fight where Caplin earns a third of its LatAm margin. The company hoards cash it won’t fully deploy or return (5% payout), dragging returns down. And the stock is near its high with no margin of safety. A patient buyer waits for the LatAm political/currency wobble — or a US-ramp disappointment — that puts it back near ₹2,000.
What the numbers actually support: A Great, Enduring, Consistent wealth creator — that much is not in doubt. The open questions are entirely about (a) whether profit keeps turning into cash, and (b) the price you pay. Watch receivable days, cash-flow-to-profit, and the Caplin Steriles run-rate. Those three, more than anything management says, will tell you next year whether the thesis is compounding or quietly leaking.
Want the full /equity-research funnel on this — moat-depth, a reverse-DCF on the US ramp, and the concall arc read line-by-line? Worth doing before any real position.
Sources
- Screener (consolidated): https://www.screener.in/company/CAPLIPOINT/consolidated/ — all hard financials, FY26.
- FY25 & FY24 Annual Reports (chairman’s letter, remuneration, segment data) — via BSE filings.
- Promoter/founder background: The CEO Magazine — C.C. Paarthipan; caplinpoint.net management team; Dr Vijay Malik analysis.
- US ramp & live issues: TradingView/Quartr FY26 summary (14 May 2026); Q4 FY26 presentation; ScanX (10 ANDAs, 2025); InvestyWise FY26 results.
- Peers: Ajanta Pharma, J B Chemicals, Gland Pharma — screener snapshots (2026-06-20).
- Assumptions: Cost of equity 12%; PAT CAGR 20% for payback projection; “RoE 20.6%” / “growth 21.9%” per screener. Concall transcript PDFs could not be fetched (certificate error) — forward guidance figures are from secondary coverage and tagged SOFT.
As of 2026-06-20. No buy/sell/hold — this is a quality verdict and a price band. The reader decides.